Jean-Marc Lapierre, PhD

Dr. Lapierre brings more than 24 years of experience in the pharma / biotech industry. Prior to joining Cyteir Therapeutics, he spent 16 years at ArQule, taking roles of increasing responsibility in the medicinal chemistry department and leading multiples programs in the field of oncology. Before moving to the east coast, Dr. Lapierre worked at Roche Bioscience (a subsidiary of Hoffmann LaRoche) in Palo Alto, California, for 8 years in the fields of inflammation and respiratory diseases. He has worked on programs targeting GPCRs, kinases, RARs and ion channels. Throughout his career, as a program team leader, chemistry team leader or medicinal chemist, he contributed to the discovery and development of several drug candidates that advanced to clinical trials (Palovarotene, Miransertib, Derazantinib, ARQ 751, ARQ 531, ARQ 736).

Dr. Lapierre obtained his BSc. in chemistry and Ph.D. in organic chemistry from the University of Montreal. He then moved to Zurich at the Eidgenossische Technische Hochschule where he did a post-doctoral training with Pr. Dieter Seebach on chiral dendrimers before joining Syntex in California where he started his industrial career in drug discovery.